加载中
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
前收盘价
US$1.93
−US$0.02 · -1.03%
盘中时间采用ET。市场数据可能有所延迟。
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
日内区间
当前US$1.93
52周区间
当前US$1.93
盘中时间采用ET。市场数据可能有所延迟。
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
日内区间
当前US$1.93
52周区间
当前US$1.93
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.43亿 USD | 9720.3万 USD | 5542.4万 USD | 3930万 USD | 3249.4万 USD |
| 销售、一般及管理费用 | 2956.7万 USD | 2793.8万 USD | 1923.6万 USD | 1483.9万 USD | 1381.9万 USD |
| 营业费用 | 1.72亿 USD | 1.25亿 USD | 7466万 USD | 5413.9万 USD | 4631.3万 USD |
| 利息收入 | 603.1万 USD | 1002.5万 USD | 698.5万 USD | 116.4万 USD | 2.4万 USD |
| 利息支出 | 200.4万 USD | 74.8万 USD | — | — | — |
| 折旧和摊销 | 164.6万 USD | 171.1万 USD | 142.6万 USD | 117.8万 USD | 73.3万 USD |
| 营业利润 | −1.72亿 USD | −1.25亿 USD | −7466万 USD | −5413.9万 USD | −4631.3万 USD |
| 净利润 | −1.68亿 USD | −1.16亿 USD | −6767.5万 USD | −5297.5万 USD | −4628.9万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$16.33
上涨空间 746.11%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1621.92万0.00%2.3万亿 USD0.03%US$381.94—
State Street SPDR S&P Biotech ETFXBI977.14万0.10%98.74亿 USD0.35%US$153.77—
iShares Russell 2000 ETFIWM836.65万0.01%787.4亿 USD0.19%US$278.94—
Vanguard Extended Market ETFVXF591.18万0.01%954亿 USD0.05%US$235—
Fidelity Enhanced Small Cap ETFFESM345.1万0.05%64.1亿 USD0.28%US$45.46—
iShares Biotechnology ETFIBB221.81万0.02%108.2亿 USD0.44%US$206.49—
Vanguard Russell 2000 ETFVTWO201.34万0.01%180亿 USD0.06%US$112.66—
iShares Russell 2000 Growth ETFIWO150.5万0.01%139.17亿 USD0.24%US$356.78—Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
